Cargando…
Oral birch pollen immunotherapy with apples: Results of a phase II clinical pilot study
BACKGROUND: Seventy percent of patients suffering from birch pollen allergy (BPA) develop a pollen‐related food allergy (prFA), especially to apples, due to a clinically relevant cross‐reactivity between the major allergen in birch Bet v 1 and Mal d 1 in apples. Therefore allergen‐specific immunothe...
Autores principales: | Nothegger, Bettina, Reider, Norbert, Covaciu, Claudia E., Cova, Valentina, Ahammer, Linda, Eidelpes, Reiner, Unterhauser, Jana, Platzgummer, Stefan, Raffeiner, Elisabeth, Tollinger, Martin, Letschka, Thomas, Eisendle, Klaus |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8127540/ https://www.ncbi.nlm.nih.gov/pubmed/33621436 http://dx.doi.org/10.1002/iid3.410 |
Ejemplares similares
-
Allergen‐specific immunotherapy with apples: selected cultivars could be a promising tool for birch pollen allergy
por: Nothegger, B., et al.
Publicado: (2020) -
Ascorbylation of a Reactive Cysteine in the Major Apple Allergen Mal d 1
por: Ahammer, Linda, et al.
Publicado: (2022) -
NMR resonance assignments of a hypoallergenic isoform of the major birch pollen allergen Bet v 1
por: Ahammer, Linda, et al.
Publicado: (2017) -
The Effect of Birch Pollen Immunotherapy on Apple and rMal d 1 Challenges in Adults with Apple Allergy
por: van der Valk, Johanna, et al.
Publicado: (2020) -
The Structural Flexibility of PR-10 Food Allergens
por: Führer, Sebastian, et al.
Publicado: (2022)